{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:40:15Z","timestamp":1787024415862,"version":"build-2736575974"},"reference-count":31,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MDER"],"DOI":"10.2147\/mder.s457152","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T06:10:06Z","timestamp":1714371006000},"page":"165-172","source":"Crossref","is-referenced-by-count":4,"title":["Reporting of Demographics & Subgroup Analyses in Premarketing Studies of FDA Approved High-Risk Cardiovascular Devices, 2014\u20132022"],"prefix":"10.2147","volume":"Volume 17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-5862","authenticated-orcid":true,"given":"Matthew","family":"Swanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Uyeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Yoder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0674-2032","authenticated-orcid":true,"given":"Sanket","family":"Dhruva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":true,"given":"Joseph","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"National Academies of Sciences, Engineering, and Medicine. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Washington, DC: The National Academies Press; 2022. doi:10.17226\/26479","DOI":"10.17226\/26479"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e217063","DOI":"10.1001\/jamanetworkopen.2021.7063","volume":"4","author":"Varma","year":"2021","journal-title":"JAMA Network Open"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1136\/medethics-2021-108068","volume":"49","author":"Varma","year":"2023","journal-title":"J Med Ethics"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e000395","DOI":"10.1136\/bmjmed-2022-000395","volume":"2","author":"Varma","year":"2023","journal-title":"BMJ Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13063-016-1322-4","volume":"17","author":"Downing","year":"2016","journal-title":"Trials"},{"key":"ref6","unstructured":"US Food & Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials guidance for industry; 2022. Available from: https:\/\/www.fda.gov\/media\/157635\/download. Accessed December 5, 2023."},{"key":"ref7","unstructured":"US Food & Drug Administration. Health of women strategic plan; 2022. Available from: https:\/\/www.fda.gov\/media\/155461\/download. Accessed December 5, 2023."},{"key":"ref8","unstructured":"US Food & Drug Administration. Food and Drug Administration Safety and Innovation Act (FDASIA); 2012. Available from: https:\/\/www.fda.gov\/regulatory-information\/selected-amendments-fdc-act\/food-and-drug-administration-safety-and-innovation-act-fdasia. Accessed December 5, 2023."},{"key":"ref9","unstructured":"US Food & Drug Administration. FDA action plan to enhance the collection and availability of demographic subgroup data; 2014. Available from: https:\/\/www.fda.gov\/media\/89307\/download. Accessed December 5, 2023."},{"key":"ref10","unstructured":"US Food & Drug Administration. Enhancing the diversity of clinical trial populations \u2014 eligibility criteria, enrollment practices, and trial designs guidance for industry; 2020. Available from: https:\/\/www.fda.gov\/media\/127712\/download. Accessed December 5, 2023."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1186\/s13063-021-05790-9","volume":"22","author":"Swanson","year":"2021","journal-title":"Trials"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamacardio.2023.3819","volume":"8","author":"Moneer","year":"2023","journal-title":"JAMA Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1001\/jama.2009.1899","volume":"302","author":"Dhruva","year":"2009","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1001\/jamainternmed.2018.3649","volume":"178","author":"Jones","year":"2018","journal-title":"JAMA Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1001\/jama.2015.8761","volume":"314","author":"Rathi","year":"2015","journal-title":"JAMA"},{"key":"ref16","unstructured":"US Food & Drug Administration. Evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies; 2017. Available from: https:\/\/www.fda.gov\/media\/98686\/download. Accessed December 14, 2023."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1001\/jama.2014.15192","volume":"312","author":"Reddy","year":"2014","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamacardio.2021.3021","volume":"6","author":"Darden","year":"2021","journal-title":"JAMA Cardiol"},{"key":"ref20","unstructured":"US Food & Drug Administration. Left Atrial Appendage Occlusion (LAAO) Devices potentially associated with procedural outcome differences between women and men Letter to Health Care Providers; 2021. Available from: https:\/\/www.fda.gov\/medical-devices\/letters-health-care-providers\/left-atrial-appendage-occlusion-laao-devices-potentially-associated-procedural-outcome-differences. Accessed December 5, 2023."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamainternmed.2017.0037","volume":"177","author":"Dhruva","year":"2017","journal-title":"JAMA Intern Med"},{"key":"ref22","unstructured":"U.S. Food and Drug Administration. Premarket Approval (PMA) Database. Available from: http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm. Accessed December 5, 2023."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5435\/JAAOS-D-22-00704","volume":"31","author":"Issa","year":"2023","journal-title":"J Am Acad Orthop Surg"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3171\/2020.10.JNS202155","volume":"136","author":"Siddiqui","year":"2021","journal-title":"J Neurosurg"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamainternmed.2017.3148","volume":"177","author":"Dhruva","year":"2017","journal-title":"JAMA Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/CIRCOUTCOMES.110.958215","volume":"4","author":"Dhruva","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/cvm-1-1-025","volume":"1","author":"Sleight","year":"2000","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-00469-4","author":"Kozlov","year":"2023","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14740338.2023.2219892","volume":"22","author":"Crisafulli","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jamaoncol.2023.0143","volume":"9","author":"Varma","year":"2023","journal-title":"JAMA Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1056\/NEJMp2215609","volume":"388","author":"Schwartz","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Medical Devices: Evidence and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=98674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=98674","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T06:10:13Z","timestamp":1714371013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/reporting-of-demographics--subgroup-analyses-in-premarketing-studies-o-peer-reviewed-fulltext-article-MDER"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":31,"URL":"https:\/\/doi.org\/10.2147\/mder.s457152","relation":{},"ISSN":["1179-1470"],"issn-type":[{"value":"1179-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}